Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH

PURPOSE: High-throughput sequencing (HTS) of immunoglobulin heavy chain genes (IGH) in unselected clinical samples for minimal residual disease (MRD) in B lymphoblastic leukemia (B-ALL) has not been tested. As current methods for MRD detection, such as flow cytometry or patient-specific qPCR are com...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Wu, David, Emerson, Ryan O., Sherwood, Anna, Loh, Mignon L., Angiolillo, Anne, Howie, Bryan, Vogt, Jennifer, Rieder, Mark, Kirsch, Ilan, Carlson, Christopher, Williamson, David, Wood, Brent L., Robins, Harlan
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5142743/
https://ncbi.nlm.nih.gov/pubmed/24970842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-3231
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares